Literature DB >> 6978152

Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model.

F F Snyder, T Lukey.   

Abstract

Metabolic regulation at a branch point may be determined primarily by relative enzyme activities and affinity for common substrate. Adenosine and deoxyadenosine are both phosphorylated and deaminated and their metabolism was studied in intact mouse thymocytes. From kinetic considerations of two activities competing for a common substrate, the deamination:phosphorylation ratio, vd/vk, at high nucleoside concentration, [S] congruent to infinity, is equal to Vd/Vk, or 34 and 1090 for adenosine and deoxyadenosine, respectively. At low substrate concentrations, [S] congruent to o, vd/vk is equal to VdKkm/VkKdm, or 0.7 and 285 for adenosine and deoxyadenosine, respectively. The analysis was extended to other mouse and human tissues by measurement of adenosine kinase, deoxyadenosine kinase and adenosine deaminase activities. All tissues were found to preferentially deaminate deoxyadenosine. Three tissue types were apparent with respect to adenosine metabolism: those which preferentially phosphorylate adenosine at all concentrations, those which switch from phosphorylation to deamination between low and high adenosine concentration and those for which deamination is quantatively important at all concentrations. Lymphoid tissues are representative of the latter category. The kinetic approach we describe offers a means of predicting nucleoside metabolism over a range of concentration which may be technically difficult to otherwise measure. The phosphorylation of adenosine and deoxyadenosine was also studied in intact thymocytes in the presence of adenosine deaminase inhibitors. The rate of deoxyadenosine phosphorylation was unaffected by coformycin or EHNA, whereas adenosine phosphorylation decreased with increasing substrate concentrations to 18% the rate in the absence of adenosine deaminase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978152     DOI: 10.1016/0167-4781(82)90061-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  The rate of the AMP/adenosine substrate cycle in concanavalin-A-stimulated rat lymphocytes.

Authors:  Z Szondy; E A Newsholme
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

2.  Inhibition of cell division by interferons. The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells.

Authors:  D R Gewert; G Moore; M J Clemens
Journal:  Biochem J       Date:  1983-09-15       Impact factor: 3.857

3.  Neonatal hepatic steatosis by disruption of the adenosine kinase gene.

Authors:  Detlev Boison; Louis Scheurer; Valérie Zumsteg; Thomas Rülicke; Piotr Litynski; Brian Fowler; Sebastian Brandner; Hanns Mohler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

4.  Entecavir competitively inhibits deoxyguanosine and deoxyadenosine phosphorylation in isolated mitochondria and the perfused rat heart.

Authors:  Avery S Ward; Chia-Heng Hsiung; Daniel G Kesterson; Vasudeva G Kamath; Edward E McKee
Journal:  J Biol Chem       Date:  2022-03-28       Impact factor: 5.486

5.  Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases.

Authors:  J Spychala; N S Datta; K Takabayashi; M Datta; I H Fox; T Gribbin; B S Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

6.  Substrate inhibition of adenosine phosphorylation in adenosine deaminase deficiency and adenosine-mediated inhibition of PP-ribose-P dependent nucleotide synthesis in hypoxanthine phosphoribosyltransferase deficient erythrocytes.

Authors:  F F Snyder; C Dyer; J E Seegmiller; R M Goldblum; G C Mills; F C Schmalstieg
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 7.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

8.  Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine.

Authors:  D E Chapman; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  An emerging role for adenosine and its receptors in bone homeostasis.

Authors:  Jack Ham; Bronwen A J Evans
Journal:  Front Endocrinol (Lausanne)       Date:  2012-09-18       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.